Search Result

Results for "

α-galactosylceramide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Biochemical Assay Reagents (1) CD1 (2) CXCR (2) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (1) Fluorescent Dye (1) Insulin Receptor (1) Interleukin Related (2) Melanocortin Receptor (1) Neuropeptide Y Receptor (2) Parasite (1) Reference Standards (1) SARS-CoV (1) Transmembrane Glycoprotein (2) Trk Receptor (1)
By Research Areas:	Cancer (6) Infection (1) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-102022

*α-Galactosylceramide* 4 Publications Verification α-GalCer; KRN7000	Transmembrane Glycoprotein Interleukin Related CD1	Inflammation/Immunology Cancer
α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor) .

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-128753

D-Lyxose	Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose with significant potential for pharmaceutical synthesis. D-Lyxose serves as a starting material for antitumor agents (such as α-galactosylceramide-based immunostimulants). D-Lyxose acts as a precursor for L-nucleoside analogs used in the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars (such as L-ribose) .

HY-166293

7DW8-5 4-Fluorophenylundecanoyl-α-galactosylceramide	Biochemical Assay Reagents	Metabolic Disease
7DW8-5 (4-Fluorophenylundecanoyl-α-galactosylceramide) is an ester product.

HY-102022R

α-Galactosylceramide (Standard) α-GalCer (Standard); KRN7000 (Standard)	Reference Standards Transmembrane Glycoprotein Interleukin Related CD1	Inflammation/Immunology Cancer
α-Galactosylceramide (Standard) is the analytical standard of α-Galactosylceramide (HY-102022). This product is intended for research and analytical applications. α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor) .

HY-172001

α-GalCer analog 8	Drug Derivative	Cancer
α-GalCer analog 8 is a triazole derivative of α-Galactosylceramide (HY-102022). α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory .

HY-137798

Chromozym PL	Fluorescent Dye	Others
Chromozym PL is a chromogenic substrate for plasmin, and the enzymatic reaction can be carried out in 0.1mL Tris-HCl buffer (50 mM, pH 7.8). 100 μM Chromozym PL was dissolved and prepared. After adding the hydrolase, the generation of p-nitroaniline (pNA) at 405 nm was continuously observed, and the hydrolysis products were calculated .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-144120

αGalCer-RBD	SARS-CoV	Infection
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain

HY-131992

N-Acetylpsychosine C2 galactosylceramide (d18:1/2:0)	Apoptosis	Inflammation/Immunology
N-Acetylpsychosine (C2 Galactosylceramide (d18:1/2:0)), α-galactosylated C2-ceramide, has immunostimulatory activity. N-Acetylpsychosine can be a useful tool to investigate the mechanism of apoptosis and the immune reponses induced by dendritic cells (DCs) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

Cat. No.	상품명	Target	Research Area

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-137798

Chromozym PL	Fluorescent Dye	Others
Chromozym PL is a chromogenic substrate for plasmin, and the enzymatic reaction can be carried out in 0.1mL Tris-HCl buffer (50 mM, pH 7.8). 100 μM Chromozym PL was dissolved and prepared. After adding the hydrolase, the generation of p-nitroaniline (pNA) at 405 nm was continuously observed, and the hydrolysis products were calculated .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

D-Lyxose	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Source Classification	Endogenous Metabolite Drug Intermediate
D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose with significant potential for pharmaceutical synthesis. D-Lyxose serves as a starting material for antitumor agents (such as α-galactosylceramide-based immunostimulants). D-Lyxose acts as a precursor for L-nucleoside analogs used in the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars (such as L-ribose) .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

α-galactosylceramide

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products